A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

17004CA088-1007-NCT06615479OpenA Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple MyelomaCA088-1007NCT06615479IndustrialAdultTreatmentIIIMultiple MyelomaDoucette, KimberleyGeorgetown University Medical Center : Gayle Cramer; Lombardi Comprehensive Cancer Center : Gayle CramerCell Therapy; Multiple MyelomaOncology GroupLombardi Comprehensive Cancer Center (LCCC)6887Gayle CramerGayle Cramer+1 202-687-1116gc604@georgetown.eduClinical Research Nurse 2 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>